Citations

Abstract Objective . Photon-counting detector (PCD) CT enables routine virtual-monoenergetic image (VMI) reconstruction. We evaluated the performance of an automatic VMI energy level (keV) selection tool on a clinical PCD-CT system in comparison to an automatic tube potential (kV) selection tool from an energy-integrating-detector (EID) CT system from the same manufacturer. Approach. Four torso-shaped phantoms (20–50 cm width) containing iodine (2, 5, and 10 mg cc −1 ) and calcium (100 mg cc −1 ) were scanned on PCD-CT and EID-CT. Dose optimization techniques, task-based VMI energy level and tube-potential selection on PCD-CT (CARE keV) and task-based tube potential selection on EID-CT (CARE kV), were enabled. CT numbers, image noise, and dose-normalized contrast-to-noise ratio (CNR d ) were compared. Main results . PCD-CT produced task-specific VMIs at 70, 65, 60, and 55 keV for non-contrast, bone, soft tissue with contrast, and vascular settings, respectively. A 120 kV tube potential was automatically selected on PCD-CT for all scans. In comparison, EID-CT used x-ray tube potentials from 80 to 150 kV based on imaging task and phantom size. PCD-CT achieved consistent dose reduction at 9%, 21% and 39% for bone, soft tissue with contrast, and vascular tasks relative to the non-contrast task, independent of phantom size. On EID-CT, dose reduction factor for contrast tasks relative to the non-contrast task ranged from a 65% decrease (vascular task, 70 kV, 20 cm phantom) to a 21% increase (soft tissue with contrast task, 150 kV, 50 cm phantom) due to size-specific tube potential adaptation. PCD-CT CNR d was equivalent to or higher than those of EID-CT for all tasks and phantom sizes, except for the vascular task with 20 cm phantom, where 70 kV EID-CT CNR d outperformed 55 keV PCD-CT images. Significance . PCD-CT produced more consistent CT numbers compared to EID-CT due to standardized VMI output, which greatly benefits standardization efforts and facilitates radiation dose reduction.

Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator–activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.

AbstractBackgroundThe detectability performance of a CT scanner is difficult to precisely quantify when nonlinearities are present in reconstruction. An efficient detectability assessment method that is sensitive to small effects of dose and scanner settings is desirable. We previously proposed a method using a search challenge instrument: a phantom is embedded with hundreds of lesions at random locations, and a model observer is used to detect lesions. Preliminary tests in simulation and a prototype showed promising results.PurposeIn this work, we fabricated a full‐size search challenge phantom with design updates, including changes to lesion size, contrast, and number, and studied our implementation by comparing the lesion detectability from a nonprewhitening (NPW) model observer between different reconstructions at different exposure levels, and by estimating the instrument sensitivity to detect changes in dose.MethodsDesigned to fit into QRM anthropomorphic phantoms, our search challenge phantom is a cylindrical insert 10 cm wide and 4 cm thick, embedded with 12 000 lesions (nominal width of 0.6 mm, height of 0.8 mm, and contrast of −350 HU), and was fabricated using PixelPrint, a 3D printing technique. The insert was scanned alone at a high dose to assess printing accuracy. To evaluate lesion detectability, the insert was placed in a QRM thorax phantom and scanned from 50 to 625 mAs with increments of 25 mAs, once per exposure level, and the average of all exposure levels was used as high‐dose reference. Scans were reconstructed with three different settings: filtered‐backprojection (FBP) with Br40 and Br59, and Sinogram Affirmed Iterative Reconstruction (SAFIRE) with strength level 5 and Br59 kernel. An NPW model observer was used to search for lesions, and detection performance of different settings were compared using area under the exponential transform of free response ROC curve (AUC). Using propagation of uncertainty, the sensitivity to changes in dose was estimated by the percent change in exposure due to one standard deviation of AUC, measured from 5 repeat scans at 100, 200, 300, and 400 mAs.ResultsThe printed insert lesions had an average position error of 0.20 mm compared to printing reference. As the exposure level increases from 50 mAs to 625 mAs, the lesion detectability AUCs increase from 0.38 to 0.92, 0.42 to 0.98, and 0.41 to 0.97 for FBP Br40, FBP Br59, and SAFIRE Br59, respectively, with a lower rate of increase at higher exposure level. FBP Br59 performed best with AUC 0.01 higher than SAFIRE Br59 on average and 0.07 higher than FBP Br40 (all P < 0.001). The standard deviation of AUC was less than 0.006, and the sensitivity to detect changes in mAs was within 2% for FBP Br59.ConclusionsOur 3D‐printed search challenge phantom with 12 000 submillimeter lesions, together with an NPW model observer, provide an efficient CT detectability assessment method that is sensitive to subtle effects in reconstruction and is sensitive to small changes in dose.

Microglia help limit the progression of Alzheimer’s disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4 , we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.

AbstractBackgroundDeep‐learning‐based image reconstruction and noise reduction methods (DLIR) have been increasingly deployed in clinical CT. Accurate image quality assessment of these methods is challenging as the performance measured using physical phantoms may not represent the true performance of DLIR in patients since DLIR is trained mostly on patient images.PurposeIn this work, we aim to develop a patient‐data‐based virtual imaging trial framework and, as a first application, use it to measure the spatial resolution properties of a DLIR method.MethodsThe patient‐data‐based virtual imaging trial framework consists of five steps: (1) insertion of lesions into projection domain data using the acquisition geometry of the patient exam to simulate different lesion characteristics; (2) insertion of noise into projection domain data using a realistic photon statistical model of the CT system to simulate different dose levels; (3) creation of DLIR‐processed images from projection or image data; (4) creation of ensembles of DLIR‐processed patient images from a large number of noise and lesion realizations; and (5) evaluation of image quality using ensemble DLIR images. This framework was applied to measure the spatial resolution of a ResNet based deep convolutional neural network (DCNN) trained on patient images. Lesions in a cylindrical shape and different contrast levels (−500, −100, −50, −20, −10 HU) were inserted to the lower right lobe of the liver in a patient case. Multiple dose levels were simulated (50%, 25%, 12.5%). Each lesion and dose condition had 600 noise realizations. Multiple reconstruction and denoising methods were used on all the noise realizations, including the original filtered‐backprojection (FBP), iterative reconstruction (IR), and the DCNN method with three different strength setting (DCNN‐weak, DCNN‐medium, and DCNN‐strong). Mean lesion signal was calculated by performing ensemble averaging of all the noise realizations for each lesion and dose condition and then subtracting the lesion‐present images from the lesion absent images. Modulation transfer functions (MTFs) both in‐plane and along the z‐axis were calculated based on the mean lesion signals. The standard deviations of MTFs at each condition were estimated with bootstrapping: randomly sampling (with replacement) all the DLIR/FBP/IR images from the ensemble data (600 samples) at each condition. The impact of varying lesion contrast, dose levels, and denoising strengths were evaluated. Statistical analysis with paired t‐test was used to compare the z‐axis and in‐plane spatial resolution of five algorithms for five different contrasts and three dose levels.ResultsThe in‐plane and z‐axis spatial resolution degradation of DCNN becomes more severe as the contrast or radiation dose decreased, or DCNN denoising strength increased. In comparison with FBP, a 59.5% and 4.1% reduction of in‐plane and z‐axis MTF (in terms of spatial frequencies at 50% MTF), respectively, was observed at low contrast (−10 HU) for DCNN with the highest denoising strength at 25% routine dose level. When the dose level reduces from 50% to 12.5% of routine dose, the in‐plane and z‐axis MTFs reduces from 92.1% to 76.3%, and from 98.9% to 95.5%, respectively, at contrast of −100 HU, using FBP as the reference. For most conditions of contrasts and dose levels, significant differences were found among the five algorithms, with the following relationship in both in‐plane and cross‐plane spatial resolution: FBP > DCNN‐Weak > IR > DCNN‐Medium > DCNN‐Strong. The spatial resolution difference among algorithms decreases at higher contrast or dose levels.ConclusionsA patient‐data‐based virtual imaging trial framework was developed and applied to measuring the spatial resolution properties of a DCNN noise reduction method at different contrast and dose levels using real patient data. As with other non‐linear image reconstruction and post‐processing techniques, the evaluated DCNN method degraded the in‐plane and z‐axis spatial resolution at lower contrast levels, lower radiation dose, and higher denoising strength.

Advanced Care at Home is a Mayo Clinic hospital-at-home (HaH) program that provides hospital-level care for patients. The study examines patient- and community-level factors that influence health outcomes. The authors performed a retrospective study using patient data from July 2020 to December 2022. The study includes 3 Mayo Clinic centers and community-level data from the Agency for Healthcare Research and Quality. The authors conducted binary logistic regression analyses to examine the relationship among the independent variables (patient- and community-level characteristics) and dependent variables (30-day readmission, mortality, and escalation of care back to the brick-and-mortar hospital). The study examined 1433 patients; 53% were men, 90.58% were White, and 68.2% were married. The mortality rate was 2.8%, 30-day readmission was 11.4%, and escalation back to brick-and-mortar hospitals was 8.7%. At the patient level, older age and male gender were significant predictors of 30-day mortality ( P -value <0.05), older age was a significant predictor of 30-day readmission ( P -value <0.05), and severity of illness was a significant predictor for readmission, mortality, and escalation back to the brick-and-mortar hospital ( P -value <0.01). Patients with COVID-19 were less likely to experience readmission, mortality, or escalations ( P -value <0.05). At the community level, the Gini Index and internet access were significant predictors of mortality ( P -value <0.05). Race and ethnicity did not significantly predict adverse outcomes ( P -value >0.05). This study showed promise in equitable treatment of diverse patient populations. The authors discuss and address health equity issues to approximate the vision of inclusive HaH delivery.

AbstractBackgroundImmunoglobulin (IG) therapy is widely used to treat primary and secondary immune deficiencies and as immunomodulatory agent for various disorders. There is great concern that shortages of IG may rise, potentially affecting medical treatment options.Study Design and MethodsAn international survey was developed to study how intravenous immunoglobulins (IVIGs) are used and managed within hospitals in case of shortages. Study data were collected and managed using REDCap electronic data capture tools hosted by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The survey was directed to hospital pharmacists and blood bank transfusion professionals and disseminated through members of the BEST Collaborative network.ResultsSurvey respondents from institutions in the USA, Canada, Europe, Japan, and Australia (n = 13) confirmed that the primary specialties utilizing IG are neurology, hematology, and immunology. More than 60% of respondents reported IG supply shortages, but mitigation strategies were not well developed.DiscussionAs IG is the leading driver in plasma demand, more studies are needed to understand current and future demand for IG from the clinical perspective. Necessity lies in establishing clinical guidance to address shortages.